CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells
Proceedings of the National Academy of Sciences · 21.07.2026 · 123 (29)
DOI: 10.1073/pnas.2601232123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 13.07.2026. Verfasst von Kapil Saxena und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, T-Lymphocytes, Cytotoxic, Cytotoxicity, Immunologic, Receptors, Antigen, T-Cell. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH (NIH), ASCO | Conquer Cancer Foundation (CCF), Cancer Prevention and Research Institute of Texas (CPRIT).
Abstract (Originalsprache)
CD8+ T cell–mediated cytotoxicity classically occurs through engagement of an alpha-beta T cell receptor (TCRαβ) with a peptide–class I major histocompatibility complex (pMHC). However, it is also known that cytotoxic CD8+ T lymphocytes (CTLs) can kill tumor cells in a pMHC-independent manner. The relative physiologic contribution and biological significance of pMHC-independent CTL killing remain unclear, and a receptor shared between CTLs and natural killer (NK) cells is generally invoked as the mechanism by which this occurs. In this study, we used acute myeloid leukemia (AML) as a model to examine mechanisms of pMHC-independent cytotoxicity and found a paradoxical TCR-dependent, MHC-independent mechanism that requires CD64. Utilizing knockouts of potential AML ligands and CTL receptors, we demonstrate that pMHC-independent cytotoxicity is a potent mechanism of CTL-mediating killing of AML cells and is largely restricted to CD64-expressing cells through an IFNγ-regulated process. Notably, we found that pMHC-independent CTL killing is not due to activation of commonly implicated NK activating receptors but rather requires an activated TCRαβ/CD3 complex. Thus, we identify a CD64-dependent, pMHC-independent, TCR-dependent mode of CTL cytotoxicity that appears highly enriched for in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
- The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030.
- Oncology Research for Biologics and Immunotherapy Translation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
- Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
ORCID-Profile: Kapil Saxena, Ke Pan, Marina Y Konopleva, Cassian Yee
Förderung
- HHS | NIH (NIH)
- ASCO | Conquer Cancer Foundation (CCF)
- Cancer Prevention and Research Institute of Texas (CPRIT)
Zitieren
APA
Saxena, K., Hung, S. H., Ryu, E., Chiu, Y., Bermack, C., Pan, K., Shi, C., Ortiz, P., Singh, S., Konopleva, M. Y., & Yee, C. (2026). CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells. Proceedings of the National Academy of Sciences, 123(29). https://doi.org/10.1073/pnas.2601232123
Vancouver
Saxena K, Hung SH, Ryu E, Chiu Y, Bermack C, Pan K, et al. CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells. Proceedings of the National Academy of Sciences. 2026;123(29). doi:10.1073/pnas.2601232123
BibTeX
@article{Saxena2026,
author = {Saxena, Kapil and Hung, Shao-Hsi and Ryu, Esther and Chiu, Yulun and Bermack, Casey and Pan, Ke and Shi, Chunhua and Ortiz, Priscilla and Singh, Shailbala and Konopleva, Marina Y and Yee, Cassian},
title = {CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {29},
doi = {10.1073/pnas.2601232123}
}
EUVIMED